Full interview: Biocept unveils revenue lift in 2Q earnings, bolsters IP portfolio
Biocept Inc (NASDAQ:BIOC) CEO Mike Nall tells Proactive the liquid biopsy provider reported a 45% boost in revenue during the second quarter of 2019, compared with the same period a year ago, driven largely by an increase in its commercial samples.
What's more, Nall says, the California-based company has been awarded three new patents in the US, Canada, and Europe, to add to its intellectual property portfolio, bringing the total to 36 patents.
Quick facts: Biocept Inc
Market Cap: $22.1 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment...FOR OUR FULL DISCLAIMER CLICK HERE